Evolus (EOLS) Set to Announce Earnings on Tuesday

Evolus (NASDAQ:EOLS) will post its quarterly earnings results after the market closes on Tuesday, May 7th. Analysts expect Evolus to post earnings of ($0.07) per share for the quarter. Investors that are interested in registering for the company’s conference call can do so using this link.

Evolus (NASDAQ:EOLS) last posted its earnings results on Thursday, March 7th. The company reported ($0.20) earnings per share for the quarter, missing the consensus estimate of ($0.15) by ($0.05). The firm had revenue of $61.00 million for the quarter, compared to analyst estimates of $61.14 million. On average, analysts expect Evolus to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Evolus Trading Up 0.6 %

Shares of Evolus stock opened at $13.30 on Monday. Evolus has a 12-month low of $7.07 and a 12-month high of $15.43. The company has a 50-day simple moving average of $13.31 and a 200 day simple moving average of $11.44.

Insider Buying and Selling

In other Evolus news, insider Rui Avelar sold 27,603 shares of the stock in a transaction on Tuesday, March 19th. The stock was sold at an average price of $13.92, for a total value of $384,233.76. Following the transaction, the insider now directly owns 372,288 shares in the company, valued at approximately $5,182,248.96. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In other news, CFO Sandra Beaver sold 5,672 shares of Evolus stock in a transaction that occurred on Tuesday, March 19th. The shares were sold at an average price of $13.92, for a total transaction of $78,954.24. Following the completion of the sale, the chief financial officer now owns 154,201 shares in the company, valued at approximately $2,146,477.92. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Rui Avelar sold 27,603 shares of Evolus stock in a transaction that occurred on Tuesday, March 19th. The stock was sold at an average price of $13.92, for a total transaction of $384,233.76. Following the sale, the insider now owns 372,288 shares of the company’s stock, valued at approximately $5,182,248.96. The disclosure for this sale can be found here. Insiders sold 49,038 shares of company stock worth $674,232 in the last quarter. Insiders own 5.40% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on the stock. Barclays upgraded shares of Evolus from an “equal weight” rating to an “overweight” rating and lifted their target price for the company from $10.00 to $16.00 in a research note on Monday, January 29th. HC Wainwright reissued a “buy” rating and issued a $27.00 price objective on shares of Evolus in a research note on Friday, March 1st. Finally, Needham & Company LLC restated a “buy” rating and set a $22.00 target price on shares of Evolus in a report on Wednesday, April 10th.

Evolus Company Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.